AlphaCrest Capital Management LLC Raises Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

AlphaCrest Capital Management LLC boosted its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL – Get Rating) by 186.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,887 shares of the company’s stock after purchasing an additional 5,129 shares during the quarter. AlphaCrest Capital Management LLC’s holdings in Omnicell were worth $686,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Wipfli Financial Advisors LLC bought a new stake in shares of Omnicell in the third quarter worth $25,000. Money Concepts Capital Corp acquired a new stake in shares of Omnicell in the 3rd quarter valued at about $27,000. Van ECK Associates Corp bought a new position in shares of Omnicell during the third quarter worth about $49,000. UMB Bank n.a. grew its stake in Omnicell by 28.5% in the third quarter. UMB Bank n.a. now owns 721 shares of the company’s stock worth $63,000 after purchasing an additional 160 shares in the last quarter. Finally, CoreCap Advisors LLC bought a new stake in Omnicell in the second quarter valued at about $101,000.

Omnicell Stock Performance

OMCL opened at $53.70 on Wednesday. Omnicell, Inc. has a twelve month low of $46.11 and a twelve month high of $138.50. The stock has a market cap of $2.42 billion, a PE ratio of 537.00, a price-to-earnings-growth ratio of 5.48 and a beta of 0.89. The business’s 50 day moving average is $54.59 and its 200-day moving average is $66.21. The company has a current ratio of 2.06, a quick ratio of 1.71 and a debt-to-equity ratio of 0.50.

Analyst Ratings Changes

OMCL has been the topic of a number of research analyst reports. KeyCorp reduced their target price on Omnicell from $70.00 to $65.00 and set an “overweight” rating on the stock in a report on Thursday, March 2nd. JPMorgan Chase & Co. dropped their target price on shares of Omnicell from $140.00 to $57.00 and set a “neutral” rating on the stock in a report on Friday, November 18th. StockNews.com raised shares of Omnicell from a “sell” rating to a “hold” rating in a report on Friday, January 13th. Wells Fargo & Company dropped their price objective on shares of Omnicell from $71.00 to $65.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 24th. Finally, SVB Leerink restated a “market perform” rating on shares of Omnicell in a research note on Friday, January 27th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $71.67.

Insider Buying and Selling at Omnicell

In other Omnicell news, EVP Scott Peter Seidelmann sold 4,436 shares of the business’s stock in a transaction on Friday, December 16th. The stock was sold at an average price of $47.79, for a total transaction of $211,996.44. Following the completion of the transaction, the executive vice president now owns 30,733 shares in the company, valued at approximately $1,468,730.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.76% of the stock is owned by company insiders.

About Omnicell

(Get Rating)

Omnicell, Inc engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation.